RaviVijMDMBA

Oncology • Saint Louis, MO

Hematologic Oncology

PROFESSOR OF MEDICINE, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Join to view full profile

Dr. Vij is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Vij's full profile

Already have an account?

Office
4921 Parkview Pl
Saint Louis, MO 63110
Phone+1 314-747-9270

Fax+1 314-454-7551
Is this information wrong?

Education & Training

George Washington UniversityMBA, Business administration, 2011 - 2013
Washington University in St. Louis School of Medicine2000
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1999
Rush University Medical CenterResidency, Internal Medicine, 1996
Maulana Azad Medical CollegeClass of 1990

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 1996 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission Start of enrollment: 2004 Jan 01
Completed
Phase 2
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Start of enrollment: 2005 Sep 01
Terminated
Phase 2
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant Start of enrollment: 2004 Jun 01
Terminated
Phase 3
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Mar 01
Terminated
Phase 2
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Aug 01
Completed
Phase 2
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma Start of enrollment: 2007 Jan 01
Completed
Phase 2
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Start of enrollment: 2006 Oct 01
Completed
Phase 1
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities Start of enrollment: 2007 Feb 01
Completed
Phase 2
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia Start of enrollment: 2008 May 01
Completed
Phase 1
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Oral Clofarabine for Acute Myeloid Leukemia Start of enrollment: 2009 Jan 01
Completed
Phase 1
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma Start of enrollment: 2008 Aug 01
Completed
Phase 2
CC-4047 (Pomalidomide) for Graft vs. Host Disease Start of enrollment: 2009 Feb 01
Completed
Phase 2
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease Start of enrollment: 2010 Oct 01
Completed
Phase 1
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 1
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 May 01
Completed
Phase 1
Azacitidine and Lenalidomide for Acute Myeloid Leukemia Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy Start of enrollment: 2010 Jan 01
Terminated
Phase 1, Phase 2
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant Start of enrollment: 2010 Apr 29
Completed
Phase 1
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Feb 01
Completed
Phase 2
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) Start of enrollment: 2010 May 01
Terminated
Phase 1
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2009 Sep 01
Completed
Phase 1, Phase 2
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) Start of enrollment: 2010 Sep 02
Completed
Phase 1
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia Start of enrollment: 2010 Oct 01
Completed
Phase 1
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors Start of enrollment: 2011 Apr 01
Completed
Phase 2
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML Start of enrollment: 2010 Nov 01
Completed
Phase 1
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Start of enrollment: 2010 Jul 15
Completed
Phase 2
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents Start of enrollment: 2011 Jun 01
Completed
Phase 2
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jul 01
Completed
Early Phase 1
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma Start of enrollment: 2012 Jun 01
Terminated
Early Phase 1
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation Start of enrollment: 2012 Sep 01
Terminated
Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Start of enrollment: 2014 Aug 25
Terminated
Phase 1
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma Start of enrollment: 2015 Jan 20
Active, not recruiting
Phase 2
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Start of enrollment: 2016 Sep 01
Active, not recruiting
Phase 2
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Start of enrollment: 2017 Nov 22
Active, not recruiting
Phase 2
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Start of enrollment: 2020 Apr 03
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple Myeloma.
Mark A Fiala, Matthew R Leblanc, Kathryn W Coccia, Shraddha Bandaru, Alice E Silberstein, Theresa Coles, Ravi Vij> ;JCO Oncology Practice. 2024 Mar 6
3 citations
Epigenetic regulation during cancer transitions across 11 tumour types.
Nadezhda V Terekhanova, Alla Karpova, Wen-Wei Liang, Alexander Strzalkowski, Siqi Chen, Yize Li, Austin N Southard-Smith, Michael D Iglesia, Michael C Wendl, Reyka G J...> ;Nature. 2023 Nov 1
1 citations
D-dimer predicts venous thromboembolism in multiple myeloma: a nested case-control study.
Sanfilippo, K., Fiala, M., Feinberg, D., Tathireddy, H., Girard, T., Di Paola, J., Vij, R., Gage, B.> ;Research and Practice in Thrombosis and Haemostasis. 2023 Nov 1
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 M...
Michael Slade, Mark A Fiala, Marie Kirchmeyer, Jeff King, Feng Gao, Mark A Schroeder, A Keith Stewart, Keith Stockerl-Goldstein, Christine Chen, Ravi Vij> ;Transplantation and Cellular Therapy. 2023 Dec 1
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation.
Ziheng Xu, Jaebok Choi, Matthew Cooper, Jeffrey King, Mark A Fiala, Jingxia Liu, Iskra Pusic, Rizwan Romee, Amanda Cashen, Meagan A Jacoby, Keith Stockerl-Goldstein, C...> ;Transplantation and Cellular Therapy. 2023 Nov 1
1 citations
Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review.
Hamlet Gasoyan, Mark A Fiala, Michelle Doering, Ravi Vij, Michael Halpern, Graham A Colditz> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
1 citations
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
Alexa J Loncharich, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark A Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Kristen M S...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
6 citations
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study.
Hira Mian, Tanya M Wildes, Ravi Vij, Matthew J Pianko, Ajay Major, Mark A Fiala> ;Blood Cancer Journal. 2023 May 10
13 citations
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Zachary D Crees, Michael P Rettig, Reyka G Jayasinghe, Keith Stockerl-Goldstein, Sarah M Larson, Illes Arpad, Giulio A Milone, Massimo Martino, Patrick Stiff, Douglas ...> ;Nature Medicine. 2023 Apr 1
3 citations
Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma.
Lijun Yao, Julia T Wang, Reyka G Jayasinghe, Julie O'Neal, Chia-Feng Tsai, Michael P Rettig, Yizhe Song, Ruiyang Liu, Yanyan Zhao, Omar M Ibrahim, Mark A Fiala, Julie ...> ;Cancer Research. 2023 Apr 14
2 citations
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study.
Michael Slade, Mark Fiala, Sarah Kelley, Zachary D Crees, Mark A Schroeder, Keith Stockerl-Goldstein, Ravi Vij> ;Leukemia Research. 2023 Apr 1
6 citations
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.
William Pilcher, Beena E Thomas, Swati S Bhasin, Reyka G Jayasinghe, Lijun Yao, Edgar Gonzalez-Kozlova, Surendra Dasari, Seunghee Kim-Schulze, Adeeb Rahman, Jonathan P...> ;NPJ Genomic Medicine. 2023 Jan 26
6 citations
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.
Erica K Barnell, Zachary L Skidmore, Kenneth F Newcomer, Monique Chavez, Katie M Campbell, Kelsy C Cotto, Nicholas C Spies, Marianna B Ruzinova, Tianjiao Wang, Brooj A...> ;Blood Advances. 2023 Jan 24
4 citations
The Dynamics of Financial Toxicity in Multiple Myeloma.
Mark A Fiala, Alice E Silberstein, Mark A Schroeder, Keith E Stockerl-Goldstein, Ravi Vij> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Apr 1
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Sandy Wong, Habib Hamidi, Luciano J Costa, Selma Bekri, Natalia Neparidze, Ravi Vij, Tina G Nielsen, Aparna Raval, Rajan Sareen, Elisabeth Wassner-Fritsch, Hearn J Cho> ;Frontiers in Immunology. 2023 Jan 1
9 citations
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.
Yao, L., Jayasinghe, R., Lee, B., Bhasin, S., Pilcher, W., Doxie, D., Gonzalez-Kozlova, E., Dasari, S., Fiala, M., Pita-Juarez, Y., Strausbauch, M., Kelly, G., Thomas,...> ;Cancer Research Communications. 2022 Oct 1
5 citations
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple mye...
Michael Slade, Thomas G Martin, Nitya Nathwani, Mark A Fiala, Michael P Rettig, Feng Gao, Abhinav Deol, Francis K Buadi, Jonathan L Kaufman, Craig C Hofmeister, Tara K...> ;Leukemia. 2022 Dec 1
34 citations
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Mye...
Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M Voorhees, Katja Weisel, Orlando F Bueno, Rajvineeth K Pothacamury, Kevin J Freise, Susan Yue, Jeremy A Ross, Akshant...> ;Journal of Clinical Oncology. 2022 Nov 1
8 citations
First-in-Humans Evaluation of Safety and Dosimetry ofCu-LLP2A for PET Imaging.
Richard Laforest, Anchal Ghai, Tyler J Fraum, Reiko Oyama, Jennifer Frye, Helen Kaemmerer, Greg Gaehle, Tom Voller, Cedric Mpoy, Buck E Rogers, Mark Fiala, Kooresh I S...> ;Journal of Nuclear Medicine. 2023 Feb 1
15 citations
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
Julie O'Neal, Julie K Ritchey, Matthew L Cooper, Jessica Niswonger, L Sofía González, Emily Street, Michael P Rettig, Susan W Gladney, Leah Gehrs, Ramzi Abboud, Julie ...> ;Leukemia. 2022 Jun 1
17 citations
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille Abboud, Ravi Vij, Keith Stockerl-Goldstein, Iskra Pusic,...> ;Transplantation and Cellular Therapy. 2022 Aug 1
75 citations
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Mohamad Mohty, Michele Cavo, Ravi Vij, Joanne Lindsey-Hill, Dominik Dytf...> ;Leukemia. 2022 May 1
9 citations
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Tra...
Matthew Mei, Raju Pillai, Soyoung Kim, Noel Estrada-Merly, Michelle Afkhami, Lixin Yang, Zhuo Meng, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjane...> ;Haematologica. 2023 Jan 1
31 citations
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors...
Guru Subramanian Guru Murthy, Soyoung Kim, Zhen-Huan Hu, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Sherif M Badawy, Amer Beitinjaneh, Chr...> ;JAMA Oncology. 2022 Mar 1
12 citations
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
Deep Hathi, Chantiya Chanswangphuwana, Nicholas Cho, Francesca Fontana, Dolonchampa Maji, Julie Ritchey, Julie O'Neal, Anchal Ghai, Kathleen Duncan, Walter J Akers, Ma...> ;Scientific Reports. 2022 Jan 7
Join now to see all

Journal Articles

Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Ravi Vij, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Practical Use of Imaging From MGUS to Myeloma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Investigational Drug May Improve Stem Cell Transplantation for Multiple Myeloma PatientsApril 17th, 2023
Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
Vij Highlights Benefits of Quadruplet Therapy for Patients with Multiple MyelomaDecember 13th, 2019
Join now to see all